A Comparative Efficacy and Safety Study of Compound Carraghenates Cream With Mayinglong Musk Hemorrhoid Ointment in the Treatment of Hemorrhoids
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01881282 |
Recruitment Status :
Completed
First Posted : June 19, 2013
Last Update Posted : February 28, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hemorrhoids | Drug: Carraghenates Cream Drug: Mayinglong Musk Hemorrhoid Ointment | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 123 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Comparative Clinical Research on Therapeutic Effect and Safety of Compound Carraghenates Cream Versus Mayinglong Musk Hemorrhoid Ointment in the Treatment of Hemorrhoids |
Study Start Date : | December 2006 |
Actual Primary Completion Date : | February 2008 |
Actual Study Completion Date : | February 2008 |

Arm | Intervention/treatment |
---|---|
Experimental: Carraghenates Cream |
Drug: Carraghenates Cream
Carraghenates cream will be administered 3-4 gram (g) each time (one sixth of a piece) through anal canal, twice a day (once in the morning and once in the evening); for consecutive 6 days. |
Active Comparator: Mayinglong Musk Hemorrhoid Ointment |
Drug: Mayinglong Musk Hemorrhoid Ointment
Mayinglong musk hemorrhoid ointment will be administered 2 g each time through anal canal, twice a day (once in the morning and once in the evening) for consecutive 6 days. |
- Pain Acting Time [ Time Frame: Day 1 up to Day 7 ]The time from the first administration of the drugs to the time when the participant feels that his (her) pain has been remitted remarkably will be assessed.
- Pain Intensity Score at Day 4 [ Time Frame: Day 4 ]Pain intensity will be measured on an 11-point numeric rating scale (NRS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates intense pain. Grade 1-4 represents mild pain, Grade 5-6 moderate pain, and Grade 7-10 serious pain. Higher score indicates worsening.
- Pain Intensity Score at Day 7 [ Time Frame: Day 7 ]Pain intensity will be measured on an 11-point numeric rating scale (NRS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates intense pain. Grade 1-4 represents mild pain, Grade 5-6 moderate pain, and Grade 7-10 serious pain. Higher score indicates worsening.
- Daily Duration of Symptoms [ Time Frame: Day 1 up to Day 7 ]The accumulated time of the onset of all symptoms in the same day will be assessed. The baseline value before the administration of the drugs is the accumulated time of the occurrence of all symptoms in the day prior to the visit.
- Frequency of Defecation [ Time Frame: Day 1 up to Day 7 ]The daily frequency of defecation for the day prior to the visit and each day during the trial period will be assessed.
- Participants' Satisfaction for the Treatment [ Time Frame: Day 7 ]Participants' will assess for the treatment satisfaction on numeric rating scale (NRS) ranging from 1 to 5, where 1= Very unsatisfactory; 2= Unsatisfactory; 3=General; 4= Satisfactory; 5= Very satisfactory.
- Assessment of Other Symptoms and Signs Including Bleeding, Edema, Local Discomfort, and Prolapse [ Time Frame: Day 1 up to Day 7 ]Participants will assess these symptoms on a score range of 0 to 3 where 0=none for all symptoms and 3= "Blood jets while defecating, and the blood jetting stops after defecation" for bleeding, "serious edema" for edema, "severe" for local discomfort and "it is difficult or unable to return the prolapsed pile" for prolapse.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 16 Years to 75 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Participants who agree to participate in the current study
- Participants having painful hemorrhoids (swollen veins in the lower part of the rectum or anus [external hemorrhoid, mixed hemorrhoid, etc.])
- Participants who did not use other topical drugs to treat their hemorrhoids a day before the inclusion
- Participants who do not use drugs other than the study drug and the control drug to treat their hemorrhoids during the study period
Exclusion Criteria:
- Participants having other anorectal diseases , such as anal fistula , anal cleft , perianal abscess , and anorectal occupied lesions etc
- Participants having hypersensitive predisposition or hypersensitive to any of components of the study drugs
- Female participants under pregnancy or during breastfeeding period
- Participants who fail to accept the scheduled visits or are lost to the visits
- Participants complicated by serious cardio cerebro vascular diseases, hepatic and renal diseases, diseases of hemopoietic system or mental disorders

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01881282
Study Director: | Johnson & Johnson Pharmaceutical Research and Development LLC Clinical Trial | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
Responsible Party: | Xian-Janssen Pharmaceutical Ltd. |
ClinicalTrials.gov Identifier: | NCT01881282 |
Other Study ID Numbers: |
CR002125 TITC-CHN-IIS-02 |
First Posted: | June 19, 2013 Key Record Dates |
Last Update Posted: | February 28, 2014 |
Last Verified: | February 2014 |
Hemorrhoids Carraghenates Mayinglong Musk Titanoreine |
Hemorrhoids Rectal Diseases Intestinal Diseases Gastrointestinal Diseases |
Digestive System Diseases Vascular Diseases Cardiovascular Diseases |